A tiny gene-editing startup just walked onto Nasdaq and did something most 2026 biotech IPOs only dream about.
It popped 67% on day one.
Scribe Therapeutics — an Alameda-based CRISPR company backed by Eli Lilly and Sanofi — priced its IPO at $15, opened at $25, and suddenly found itself sitting on a $440 million market cap.
And yes… this is the same Scribe you might have heard whispered about in biotech circles. The one quietly rewriting how we think about heart disease.
The raise itself tells you everything about investor appetite.
And on top of that, Sanofi affiliates quietly grabbed $7.5M in a concurrent private placement.
Eli Lilly? Already an existing backer — and signalled it wanted to bump its stake to as much as 11%.
When Big Pharma is elbowing its way into your cap table, the market notices.
This isn't another oncology moonshot.
Scribe is going after the world's #1 killer: heart disease.
Its lead program, STX-1150, is a CRISPR epigenetic silencing therapy targeting PCSK9 — the gene that controls bad cholesterol (LDL-C).
The pitch is wild:
One dose. Durable LDL reduction. Potentially for life.
No daily statins. No injections every few months. Just… edit the switch and walk away.
Scribe is chasing atherosclerotic cardiovascular disease (ASCVD) first — the plaque-in-your-arteries condition that quietly kills millions every year.
Initial trial data is expected out of Australia in the first half of 2027.
And the runway just got a lot longer:
Scribe is still burning cash — a $17.4M net loss last quarter on just $2.2M in collaboration revenue.
No approved drug. No pivotal data. Years from a commercial product.
And yet the market handed it a nine-figure war chest and a two-thirds pop on day one.
Because the story it's selling is irresistible:
What if heart disease became a one-time fix, not a lifetime prescription?
That's the bet Lilly is making. That's the bet Sanofi is making.
And on Friday, Wall Street bought a ticket to the same ride.
That's all for now!
